Acorda Therapeutics Names Jane Wasman President, International

Acorda Therapeutics (NASDAQ: ACOR) today announced that it has
named Jane Wasman as President, International. Ms. Wasman most recently
has served as Acorda's Chief, Strategic Development and General Counsel.
In her new role, Ms. Wasman will lead the Company's efforts to identify
and launch in-licensing and commercial opportunities outside the United
States. She will also be responsible for managing Acorda's collaboration
with Biogen Idec (Nasdaq: BIIB) in their international development and
commercialization of FAMPYRA® (prolonged-release fampridine
tablets). Ms. Wasman will also continue to lead the Company's global
strategic development and will retain the title of General Counsel and
Corporate Secretary.

“I am delighted that Jane will be spearheading our proactive efforts to

See full press release